(SIGA) SIGA Technologies - Ratings and Ratios

SIGA Technologies, Inc. (NASDAQ:SIGA), a commercial-stage pharmaceutical company, specializes in developing and commercializing solutions for health security threats, with a primary focus on the U.S. market. Its lead product, TPOXX (tecovirimat), is an orally administered antiviral drug approved by the FDA for the treatment of smallpox caused by the variola virus. TPOXX is also approved for the prevention of smallpox and has demonstrated efficacy against other orthopoxviruses, such as monkeypox. The company has secured significant government contracts, including a multi-year agreement with the U.S. Department of Health and Human Services to supply TPOXX for the Strategic National Stockpile. SIGA was founded in 1995 and is headquartered in New York, New York.

Over the next three months, SIGAs stock price is expected to face headwinds due to technical resistance levels indicated by its SMA 20 (5.89) and SMA 50 (6.06), which are currently above the last price (5.42). The SMA 200 (7.35) further suggests downward pressure. However, the companys strong financial position, with a market cap of $504.12M and a return on equity (RoE) of 50.58, indicates resilience. The low ATR (0.25) signals moderate volatility, while the forward P/E (4.55) and P/S (2.34) suggest undervaluation potential. Overall, SIGAs stock may experience short-term weakness but could stabilize as its fundamentals remain robust.